Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CANCER NURSING: SARS-COV-2 AND CANCER NURSING

CN26
Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland: A qualitative study
S. Colomer-Lahiguera1, K. Ribi2, C.M. Witt3, M. Eicher1
1Institute of Higher Education and Research in Health Care IIURS, Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland; 2Quality of Life Office Dept, IECBS International Breast Cancer Study Group, Bern, Switzerland; 3Institute for Complementary and Integrative Medicine, University Hospital Zürich, Zurich, Switzerland

Background: Impact of the COVID-19 outbreak on cancer patients may be high in terms of anxiety, fear and psychological distress; however, this topic remains under-addressed. We aim to describe cancer patient experiences related to the COVID-19 pandemic in Switzerland. Information gained through in-depths interviews will be triangulated with the level of distress and resilience.

Methods: Purposive sampling will be used to recruit four patient subgroups diagnosed with melanoma, breast, lung, or colon cancer (i) under adjuvant treatment; (ii) under anti-cancer treatment with palliative intent; (iii) being consulted at institutes for complementary and integrative medicine (ICIM); (iv) being consulted by clinical nurse specialists (CNS). Interview guides were developed based on qualitative analysis of public online cancer patients’ forums from four different countries. We selected main posts related to COVID-19. Semantic and inductive thematic analysis approaches were used to identify meaningful patterns and themes. The level of distress and resilience will be measured by the NCCN Distress Thermometer and the 2-item Connor-Davidson Resilience Scale. We aim to include 120 patients (10 participants per subgroup in each language region). Recruitment will start in September 2020.

Results: The design of the study as well as preliminary data regarding themes and subthemes identified in the patient’s forum analysis will be presented.

Conclusions: To the best of our knowledge, no patient experience study with a qualitative design is conducted or planned within cancer patients during COVID-19 pandemic in Europe. The study will serve to identify concerns, unmet information and clinical needs and potential positive experiences of patients with cancer in relation to the COVID-19 pandemic. Newly developed patient reported measures should be based on qualitative data. The identification of topics considered important to patients will thus support the development of patient reported experience measures for the current or future epidemics/pandemics.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: S. Colomer-Lahiguera: Travel/Accommodation/Expenses: Vifor pharma. M. Eicher: Travel/Accommodation/Expenses: Vifor pharma; Honoraria (institution): Vifor pharma; Honoraria (institution): Research grant/Funding (institution): BMS; Honoraria (institution): Research grant/Funding (institution): Roche; Honoraria (institution): Research grant/Funding (institution): Kaiku Health. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.jonm.2020.08.2134

CN27
Value of nurse navigators (NNs) telemonitoring for cancer patients (pts) tested positive for COVID-19
D. Mathivon1, M. Abbas1, A. Barrais1, A. Dufflot-Boukobza1, M. Ferrua2, J. Legendre1, C. Menders1, M. Merad1, E. Minvielle1, O. Mir1, M. Pons1, F. Scotté1
1Care Pathways, Gustave Roussy, Villejuif, France; 2Research Department, Gustave Roussy, Villejuif, France

Background: The current COVID-19 pandemic has raised a major challenge to healthcare systems. Deployment of telehealth solutions can help maintaining continuity of care. The request to stay at home particularly applied to cancer patients, who were considered at higher risk for infection and severe events. Patients had to experience substantial psychosocial implications of mass quarantine and they were also faced with special challenges to receive safe cancer care. This study aimed to investigate the perspectives of people living with cancer during mass quarantine.

Methods: The Italian Association of Cancer Nurses (AIANO) conducted an online survey from March 29th to May 3rd, 2020, which corresponds to “Phase One” of the COVID-19 Italian emergency plan. People living with cancer and self-isolated at home were invited to fill the survey via social groups. Data about socio-demographic and clinical characteristics, opinion on the impact of SARS-CoV-2, access to cancer care, behavioural measures implemented, and the perception of being isolated (ISOLA scale) were collected.

Results: Participants were 195 adults living with cancer (female=76%, mean age=50.3±11.2 years). They were more often affected by haematological malignancy (51.3%) and staying at home with partner and children (38.3%) for more than 4 weeks (70.8%). Only 54% of them believed to be at higher risk for SARS-CoV-2 infection and 51% for severe complications. Measures to prevent the infection included hand washing (95.2%), social distancing (81.5%), face mask (96.3%), gloves (55.6%), and remedies to boost their immune system (29%). Overall, 62% reported diminished/access absent to cancer care and 29% were afraid that their cancer was not under control. The mean scores of the ISOLA scale (range 1-5) were 2.9 (SD=0.81) for isolation-related suffering, 3.31 (SD=1.13) for problems in the relationship with others, and 3.14 (SD=1.06) for difficulties in the relationship with oneself. Greater social isolation in quarantine was reported by the older patients, with lower education, and living without children.

CN29
SARS-Cov-2 and the perspectives of people living with cancer: The AIANO survey on the Italian lockdown
V. Bioggi1, S. Belloni2, B. Albarelli3, A. Pireddda1, R. Caruso2
1Department of Medicine and Psychology, Sapienza - Università di Roma, Roma, Italy; 2Biomedicine and Prevention, Tor Vergata University, Roma, Italy; 3Associazione Italiana degli Infermieri di Area Oncologica (AIANO), European Institute of Oncology, Milan, Italy; Health Professions Research and Development Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy

Background: On March 9th, the lockdown was enforced in Italy to contain the spread of the SARS-CoV-2 pandemic. The request to stay at home particularly applied to cancer patients, who were considered at higher risk for infection and severe events. Patients had to experience substantial psychosocial implications of mass quarantine and they were also faced with special challenges to receive safe cancer care. This study aimed to investigate the perspectives of people living with cancer during mass quarantine.

Methods: The Italian Association of Cancer Nurses (AIANO) conducted an online survey from March 29th to May 3rd, 2020, which corresponds to “Phase One” of the COVID-19 Italian emergency plan. People living with cancer and self-isolated at home were invited to fill the survey via social groups. Data about socio-demographic and clinical characteristics, opinion on the impact of SARS-CoV-2, access to cancer care, behavioural measures implemented, and the perception of being isolated (ISOLA scale) were collected.

Results: Overall, 116 COVID-positive pts have completed the monitoring period (median age: 58.5 years, 21-90; 56.9% female). 54.3% were monitored after hospitalization for COVID-19, 37.1% after RT-PCR screening (symptomatic pts) and 8.6% after systematic screening prior to surgery. There were no deaths or admissions to intensive care unit. 7.8% of pts were hospitalized (excluding scheduled hospitalization). NNs conducted an average of 9.9 calls per patient. Of 53 events requiring a medical opinion, 50.9% resulted in a visit to the emergency room. 41.4% of pts downloaded the CAPRI App, and completed the tracking data on average 1.1 times per day.

Conclusions: CAPRI-COVID enabled to keep the majority of pts at home, and helped to ensure secure pts’ pathways during this epidemic. NNs play an essential role in addition with the use of CAPRI App which helped limiting phone calls and focusing on the management of complex pts. Ongoing analyses are exploring actions of NNs and pts’ experience.

Legal entity responsible for the study: Gustave Roussy.

Funding: Has not received any funding.

Disclosure: O. Mir: Honoraria (self), Travel/Accommodation/Expenses: Agenor; Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Bayer; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Blue-Print Medicines; Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Eli Lilly; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Shareholder/Stockholder/Stock options: Ipsen; Honoraria (self): Lundbeck; Honoraria (self): MSD; Honoraria (self), Honoraria (institution): Novartis; Honoraria (self), Honoraria (self), Honoraria (institution): Roche; Expert testimony, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Honoraria (self), Speaker Bureau/Expert testimony: Servier; Honoraria (self), Vifor Pharma; Shareholder/Stockholder/Stock options: Amplitude Surgical; Honoraria (self), Shareholder/Stockholder/Stock options: Transgene; Honoraria (institution): PharmaMar. F. Scotté: Honoraria (self): CIO Roche; Honoraria (self): MSD; Honoraria (self): Pierre Fabre Oncology; Honoraria (self): Leo Pharma; Honoraria (self): BMS; Honoraria (self): Pfizer; Honoraria (self): Mundi Pharma; Honoraria (self): Mylan. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.jonm.2020.08.2135